Hello, we're Nonacus

Looking for Informed Genomics? You’ve found us! In May 2025, we began trading as Nonacus Clinical Services to be better aligned with our sister company Nonacus. We’re the same team, offering the same accredited services, we just look a little different.

Nonacus

We are creating a world where early cancer diagnosis, detection and management is simple and universally available.

One great example of how we are making our mission a reality can be seen with GALEAS Bladder – our non-invasive test for bladder cancer that removes the need for unnecessary, invasive and expensive hospital procedures. This benefits:

Patients – who receive earlier diagnosis, care and treatment – critical for improving health outcomes

Clinicians – by reducing waiting lists and appointments, clinicians can focus on the patients that urgently need attention

Healthcare providers – our solutions can significantly speed up the time it takes for patients to get results, and save the NHS millions of pounds, every year!

That’s the impact of just one of our tests. Find out more about our quality-driven, patient-focused solutions and clinical services.

Find out more

A decade of innovation

In 2025, we celebrate our 10th anniversary and a decade of delivering non-invasive firsts! The unwavering ambition of our dedicated team has enabled us to achieve remarkable growth and innovation, fuelled by the vision of our co-founders.

2015

Nonacus opens for business

2015

2019

Launch custom Next Generation Sequencing (NGS) panels

2019

2020

Develop the first Covid spit test, and launch Whole Genome Sequencing (WGS) service to support SARS

2020

2021

Develop 1st pan-cancer NHS panel for liquid biopsy
Receive funding for Covid NHS and surveillance

2021

2022

Launch Informed Genomics, to deliver UKAS-accredited clinical services
Move to new purpose-built offices and laboratory in Birmingham

2022

2023

Launch Gales Bladder, a urine test for bladder cancer

2023

2024

Launch Galeas Hereditary Cancer Panels
NHS began service evaluation of Galeas Bladder
Launch ESR-1, first ultra-sensitive qPCR assay

2024

2025

Launch Galeas Tumor for HRD
Informed Genomics begins trading as Nonacus Clinical Services

2025

Looking ahead, we are excited to embark on the next chapter. This includes continuing to expand our global reach, build a vibrant community of scientists and researchers, and continuously push the boundaries of NGS technology to drive earlier cancer detection, for everyone.

Want to join us in our mission? Discover the latest vacancies

How it all began

Our story begins with two scientists and a shared aim - to develop non-invasive DNA tests that would transform genomic diagnostics.

Chris Sale and Lee Silcock founded Nonacus in 2015. Based on the Latin term 'non acus' meaning 'no needle', Nonacus symbolises the company's mission - to move away from intrusive, risky diagnostic procedures like tissue biopsies or amniocentesis and towards less invasive testing to improve patient experiences, redefine standard of care and open new possibilities for monitoring and treatment.

Meet Jeff, our CEO

"Nonacus is solving problems that will improve the lives of billions worldwide through the universal availability of early cancer diagnosis, detection and management.”

Jeff Bousfield

CEO, Nonacus

Meet the team

As a senior leadership team, we bring together clinical, scientific and commercial expertise to deliver value to our customers and improve the lives of patents around the world.

Becky Lamont

Marketing Manager

20+ years leading brand, communications and PR for technology, healthcare and life sciences organisations.

Bruno Ping

Chief Operating Officer

20 years in clinical diagnostics, formerly leading one of the UK’s biggest labs processing 45,000 samples a day.

Chris Sale

Chief Strategy Officer and Co-founder

Leading industry voice with 25+ years’ experience in genomics & diagnostics. Previously led European sales teams at leading genetic companies, Illumina and Agilent.

Jeff Bousfield

Chief Executive officer

10+ years scaling high-growth companies into new markets alongside £200m in fundraising and M&A. Returned to life sciences in 2023 to lead Nonacus, following 10 years in tech and 5 years at GSK.

Karen Cook

Commercial Product Director

20 years in genetics, formerly leading NGS sales for Illumina and product for Minnac Life Sciences.

Lee Silcock

Chief Product Officer and Co-founder

Scientific leader with 20+ years’ experience within laboratory, clinical science and bioinformatics. After training as a clinical scientist with the NHS, Lee moved into frontline scientific support for Agilent.

Michael Parks

Director of Laboratory Operations

12 years translating non-invasive genetic testing from proof of concept to clinical solutions.

Samuel Clokie

Director of Bioinformatics, Data Science & Software

Directed bioinformatics for 9 years at the largest NHS genetics lab in the UK (WMRGL). Gained multi-omics experience, including NGS, over 7 years working as a Research Fellow at the National Institutes of Health (NIH), USA.

Simon Davis

Chief Commercial Officer

Commercialising products and services, recently building our flagship hereditary cancer testing service to support the NHS and private sector. Prior to Nonacus, Simon led several diagnostic and pharmaceutical product launches into the UK healthcare system.